



Cite this: *Dalton Trans.*, 2016, **45**, 8945

Received 14th March 2016

Accepted 3rd May 2016

DOI: 10.1039/c6dt01001f

www.rsc.org/dalton

# Coordination chemistry of a calix[4]arene-based NHC ligand: dinuclear complexes and comparison to $\text{I}^i\text{Pr}_2\text{Me}_2^\dagger$

Ruth Patchett and Adrian B. Chaplin\*

The preparation and coordination chemistry of 5,17-bis(3-methyl-1-imidazol-2-ylidene)-25,26,27,28-tetrapropoxycalix[4]arene (**1**) is described. Starting from the bis(imidazolium) pro-ligand **1.2HI**, the free carbene **1** was readily generated in solution through deprotonation using  $\text{K}[\text{O}^t\text{Bu}]$  and its reactivity with rhodium(i) dimers  $[\text{Rh}(\text{COD})\text{Cl}]_2$  (COD = 1,5-cyclooctadiene) and  $[\text{Rh}(\text{CO})_2\text{Cl}]_2$  investigated. Dinuclear complexes were isolated in both cases, where the calix[4]arene-based NHC ligand adopts a bridging  $\mu^2$ -coordination mode, and in one case characterised in the solid-state by X-ray diffraction. Using instead an isolated and well-defined (mononuclear) silver transfer agent, generated by reaction of **1.2HI** with  $\text{Ag}_2\text{O}$  in the presence of a halide extractor, reactions with  $[\text{Rh}(\text{COD})\text{Cl}]_2$  and  $[\text{Rh}(\text{CO})_2\text{Cl}]_2$  produced cationic dinuclear complexes bearing  $\mu^2$ -**1** and  $\mu^2$ -Cl bridging ligands. The structural formulation of the novel dinuclear adducts of **1** was aided through spectroscopic congruence with model complexes, containing monodentate 1,3-diisopropyl-4,5-dimethylimidazol-2-ylidene ( $\text{I}^i\text{Pr}_2\text{Me}_2$ ).

## Introduction

In addition to desirable donor properties, the structural versatility of N-heterocyclic carbenes (NHCs) has proven to be a major contributing factor in the widespread application of these ligands throughout organometallic chemistry and catalysis.<sup>1</sup> The root of this diversity lies in the numerous and generally straightforward preparative procedures available for the construction of the respective NHC pro-ligands; synthetic methodologies that have enabled access not only a plethora of monodentate ligands, but also an extensive range of polydentate variants.<sup>2,3</sup>

As polydentate ligand scaffolds, calix[4]arenes are well suited building blocks with scope for functionalisation across the upper and/or lower rims of these 'bowl' shaped macromolecules.<sup>4</sup> Despite extensive investigation of heteroatom-based donor systems, the coordination chemistry of NHC-functionalized calix[4]arenes is not well developed.<sup>5</sup> 5,17-Difunctionalised examples, bearing NHC donors on opposite faces of the upper rim, are of particular interest for positioning bound metal centres across the macrocycle cavity. Well-defined complexes of these ligands are, however, limited to imidazol-2-

ylidene based **A–D** (Chart 1). Complexes **A** illustrate this principle well, positioning square planar palladium centres directly over the macrocycle cavity.<sup>6</sup> The incorporation of a methylene spacer between the calix[4]arene rim and the NHC donor group in **B** results instead in unfavourable twisting of the donor groups that skews the bound metal centres to one side of the ligand, while in **C** and **D**, the cavity is pinched closed as




Chart 1 Complexes of upper rim functionalised calix[4]arene NHC and phosphine ligands.

Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK. E-mail: a.b.chaplin@warwick.ac.uk

† Electronic supplementary information (ESI) available:  $^1\text{H}$  and  $^{13}\text{C}$  NMR, IR and ESI-MS spectra of new complexes. CCDC 1448987–1448996. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c6dt01001f






Chart 2 NHC systems of interest.

a consequence of the *cis*-coordination geometry of the metal centres.<sup>7</sup> Closely related to **A**, phosphine-based systems **E** have also been described, where the ligand backbone enforces *trans*-coordination.<sup>8,9</sup>

In this report the preparation and coordination chemistry of an upper rim functionalised calix[4]arene pro-ligand **1**·2HI are described (Chart 2). Through generation of the free NHC ligand (**1**) and use of transmetallation methodology, reactions with rhodium(I) dimers [Rh(COD)Cl]<sub>2</sub> (COD = 1,5-cyclooctadiene) and [Rh(CO)<sub>2</sub>Cl]<sub>2</sub> lead to a range of dinuclear complexes containing either discrete or chloro-bridged metal fragments depending on the reagents employed. To help understand the influence of the calix[4]arene scaffold and corroborate the structural formulations of these species, the spectroscopic characteristics of complexes of **1** are contrasted with analogues containing the monodentate NHC ligand *i*Pr<sub>2</sub>Me<sub>2</sub>.<sup>10</sup>

## Results and discussion

The synthesis of 5,17-(3-methyl-1-imidazole)-functionalised pro-ligand **1**·2HI was achieved through straightforward adaption of literature protocols for related *N*-butyl and *N*-isopropyl analogues, involving alkylation of **F** with methyl iodide and isolated in 84% yield (Scheme 1).<sup>11</sup> The known precursor **F** was obtained following a five step synthesis, starting from commercially available 4-*tert*-butylcalix[4]arene (*ca.* 2 weeks, 8% yield in our hands), giving an overall yield of 7% for the six step procedure.<sup>12</sup> The formation of the new bis(imidazolium) salt was fully corroborated through a combination of NMR spectroscopy, ESI-MS, combustion analysis and X-ray crystallography. In solution the pre-carbenic centre is characterized by <sup>1</sup>H and <sup>13</sup>C resonances at  $\delta$  9.20 and  $\delta$  134.9 (CD<sub>2</sub>Cl<sub>2</sub>), respectively, while the mass spectrum showed a strong dication

signal centred at 377.2220 *m/z* (calcd 377.2224) with half-integer spacing. The solid-state structure features two independent but structurally similar dication that adopt distinctive 'pinched-cone' conformations, reflecting intra-charge repulsion between the imidazolium groups (C2...C8, 13.43(2) Å/C102...C108, 13.09(2) Å; Fig. 1).<sup>13</sup> In order to quantify this distortion, the angles between the least squares planes (Mpln) of opposing aryloxy groups  $\theta_{\text{CALIX}}(\text{R})$ , where R = the aryl *para* substituent and the sign reflects the relative disposition of the R substituents (+ve, outwards; -ve, inwards), have been measured. Using this approach distortion from an ideal *C*<sub>4v</sub> symmetric 'cone' to *C*<sub>2v</sub> symmetric 'pinched cone' conformation of the calix[4]arene skeleton was found to be most pronounced in the independent molecule shown in Fig. 1 with  $\theta_{\text{CALIX}}(\text{NHC}\cdot\text{H}^+)/\theta_{\text{CALIX}}(\text{H}) = +80.8(2)/-19.3(2)^\circ$  ( $\Delta\theta_{\text{CALIX}} = 100.1(4)^\circ$ ); the other is characterised by  $\theta_{\text{CALIX}}(\text{NHC}\cdot\text{H}^+)/\theta_{\text{CALIX}}(\text{H}) = +86.4(2)/-2.8(2)^\circ$  ( $\Delta\theta_{\text{CALIX}} = 89.2(4)^\circ$ ).

Deprotonation of **1**·2HI with strong hindered base K[O<sup>*t*</sup>Bu] in C<sub>6</sub>D<sub>6</sub> or d<sub>8</sub>-THF at 293 K resulted in quantitative formation of the free carbene **1**, which was thoroughly characterised *in situ* using NMR spectroscopy. The deprotonation was corroborated by the absence of the <sup>1</sup>H NCHN resonance and characteristically high frequency <sup>13</sup>C resonance at  $\delta$  213.2





Fig. 1 Solid-state structure of **1**·2HI. Thermal ellipsoids for selected atoms drawn at the 30% probability level; only one of the two unique molecules shown (*Z* = 2); hydrogen atoms and anions are omitted for clarity. Selected bond lengths (Å) and angles (°): C2...C8, 13.43(2);  $\angle\text{Mpln}(\text{C13}-\text{C18},\text{O41})-\text{Mpln}(\text{C27}-\text{C32},\text{O49})$ , 80.8(2);  $\angle\text{Mpln}(\text{C20}-\text{C25},\text{O45})-\text{Mpln}(\text{C34}-\text{C39},\text{O53})$ , 19.3(2); C102...C108, 13.09(2);  $\angle\text{Mpln}(\text{C113}-\text{C118},\text{O141})-\text{Mpln}(\text{C127}-\text{C132},\text{O149})$ , 86.4(2);  $\angle\text{Mpln}(\text{C120}-\text{C125},\text{O145})-\text{Mpln}(\text{C134}-\text{C139},\text{O153})$ , 2.8(2).



Scheme 1 Preparation and deprotonation of pro-ligand **1**·2HI.




(C<sub>6</sub>D<sub>6</sub>)/216.0 (d<sub>8</sub>-THF) of the carbenic centre.<sup>14</sup> For comparison, the equivalent signal in <sup>1</sup>IPr<sub>2</sub>Me<sub>2</sub> is located at δ 212.7 (C<sub>6</sub>D<sub>6</sub>).<sup>10</sup> Multiple attempts at isolating **1** from solution proved unsuccessful and instead it was generated *in situ* in subsequent studies.

Reactions of **1**, generated as described above, with rhodium(I) dimers [Rh(COD)Cl]<sub>2</sub> and [Rh(CO)<sub>2</sub>Cl]<sub>2</sub> were explored in THF, using excess KI (*ca.* 10 equiv.) to avoid formation of mixed halide products. Using either 0.5 or 1 equiv. of rhodium precursor per ligand, the only well-defined species that could be identified were dinuclear complexes **2a** and **3a**, where **1** adopts a bridging μ<sup>2</sup>-coordination mode (Scheme 2). In this manner, rhodium-diene-based **2a** was obtained in good isolated yield of 53% following purification over alumina. Isolation of **3a**, however, proved to be very low yielding (*ca.* 17%) and in order to acquire a more meaningful quantity of **3a**,

alternative preparation from **2a** *via* diene displacement with CO (1 atm) in CH<sub>2</sub>Cl<sub>2</sub> solution was required (quantitative conversion by <sup>1</sup>H NMR spectroscopy, 37% isolated yield). Mononuclear analogues of these new complexes bearing <sup>1</sup>IPr<sub>2</sub>Me<sub>2</sub>, **2b** and **3b**, were readily obtained through direct adaptations of the aforementioned procedures (Scheme 2).

For both NHC ligands, the rhodium-diene complexes **2** were characterised in the solid-state by X-ray crystallography (Fig. 2). The conformation of the calix[4]arene backbone in **2a** is notable for a dramatic conformational inversion in comparison to the pro-ligand 1·2HI, that appears to be driven by a favourable (off-centre) π-stacking interaction between the imidazolylidene rings (Cnt-Cnt = 3.608(5) Å; Δθ<sub>CALIX</sub> = -98.41(12)°, **2a**; 100.1(4)/89.2(4)°, 1·2HI), and pseudo C<sub>2</sub> symmetry. As expected for d<sup>8</sup>-metal complexes of this type, the rhodium centres adopt square planar coordination geometries in **2** and the associated metal-ligand bonding metrics are in line with related literature precedents.<sup>15</sup> The similarity of the metal-NHC bonding characteristics in the new systems is apparent in both the solid-state (Rh-C = 2.021(3)/2.024(3) Å, **2a**; 2.021(3) Å, **2b**) and in solution by <sup>13</sup>C NMR spectroscopy [δ 180.4 (<sup>1</sup>J<sub>RhC</sub> = 49 Hz), **2a**; 178.4 (<sup>1</sup>J<sub>RhC</sub> = 49 Hz), **2b**]. The structures were fully corroborated in solution by <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy, with intact coordination of the diene ligands readily established by presence of alkene <sup>13</sup>C signals at *ca.* δ 95 (<sup>1</sup>J<sub>RhC</sub> = 7 Hz) and 72 (<sup>1</sup>J<sub>RhC</sub> = 14 Hz) displaying coupling to <sup>103</sup>Rh. Loss of C<sub>s</sub> symmetry in the {Rh(COD)} fragment and C<sub>2v</sub> symmetry of the ligand **1** is observed on complexation, with C<sub>2</sub> symmetry evident on inspection of the <sup>1</sup>H and <sup>13</sup>C{<sup>1</sup>H} NMR spectra of **2a**. Moreover, a large difference in chemical shift is observed for the now inequivalent <sup>1</sup>H resonances of the imidazolylidene functionalised aryl ring (Δδ = 2.03), with the high frequency signal at δ 7.95 presumably a consequence of the close



Scheme 2 Reactions of **1** and <sup>1</sup>IPr<sub>2</sub>Me<sub>2</sub> with rhodium dimers.




Fig. 2 Solid-state structures of **2a** and **2b**. Thermal ellipsoids for selected atoms drawn at the 50% probability level; minor disordered components (two O<sup>*t*</sup>Pr groups in **2a**), and hydrogen atoms omitted for clarity. Selected bond lengths (Å) and angles (°): **2a**: Rh1–I3, 2.6905(3); Rh1–Cnt(C5,C6), 2.089(3); Rh1–Cnt(C9,C10), 2.001(3); Rh1–C21, 2.021(3); Rh2–I4, 2.6934(3); Rh2–Cnt(C13,C14), 2.098(3); Rh1–Cnt(C17,C18), 1.990(4); Rh2–C27, 2.024(3); Rh1...Rh2, 8.5698(3); Cnt(C21–N25)–Cnt(C27–N31), 3.608(5); ∠Mpln(C33–C38,O61)–Mpln(C47–C52,O69), 22.35(6); ∠Mpln(C40–C45,O65)–Mpln(C54–C59,O73), 76.06(6); **2b**: Rh1–I2, 2.6729(2); Rh1–Cnt(C3,C4), 2.109(2); Rh1–Cnt(C7,C8), 2.00(3); Rh1–C11, 2.021(3).




proximity of the halogen atom (*cf.*  $C-H \cdots I = 4.139(3)/4.295(3)$  Å observed in the solid-state and  $\delta$  6.61 for 1·2HI), as previously noted in a related calix[4]arene-based system.<sup>5b</sup> Combined, these NMR data of **2a** are consistent with retention of solid-state structure in solution.

Although, we have so far been unable to grow suitable samples of **3** for structural elucidation by X-ray crystallography, the solution data points strongly to equivalent structural formations as **2**. For instance, the relative *cis*-configuration of the carbonyl ligands was established through observation of two bands in the respective IR spectra ( $\nu(CO) = 2071, 2002$ , **3a**; 2072, 1998  $cm^{-1}$ , **3b**) and two distinct high frequency doublet resonances in the  $^{13}C\{^1H\}$  NMR spectra [ $\delta$  188.4 ( $^1J_{RhC} = 54$  Hz), 181.6 ( $^1J_{RhC} = 78$  Hz), **3a**; 188.7 ( $^1J_{RhC} = 53$  Hz), 182.7 ( $^1J_{RhC} = 78$  Hz), **3b**].  $^1H$  and  $^{13}C\{^1H\}$  NMR spectra of **3a** also exhibit  $C_2$  symmetry. In comparison to **2**, the carbenic resonances are notable for a shift to lower frequency by *ca.* 10 ppm and there is a reduction in the magnitude of the coupling to  $^{103}Rh$  [ $\delta$  171.5 ( $^1J_{RhC} = 44$  Hz), **3a**; 166.8 ( $^1J_{RhC} = 41$  Hz), **3b**].

To further explore the coordination chemistry of **1**, we sought to utilise widely employed transmetalation methodology based on silver transfer agents.<sup>1c,16</sup> To this end, 1·2HI was reacted with a slight excess of  $Ag_2O$  in the presence of Na[ $BAR^F_4$ ] ( $Ar^F = 3,5-C_6H_3(CF_3)_2$ ), as a halide extractor, resulting in chelation of **1** and subsequent isolation of **4a** in 73% yield (Scheme 3). The structural formulation of the new silver(I) complex was readily established in solution through a combination of  $^1H$  and  $^{13}C$  NMR spectroscopy and ESI-MS. The  $^1H$  NMR spectrum of isolated **4a** shows  $C_{2v}$  symmetry, with the *N*-methyl signal located to lower frequency than found in the pro-ligand ( $\delta$  3.80 vs. 4.17). A strong parent ion is observed by ESI-MS in positive ion mode at 859.3340  $m/z$  (calcd 859.3347  $m/z$ ) with a correct isotope pattern. Moreover the cation : [ $BAR^F_4$ ] ratio was verified by integration of  $^1H$  NMR data and elemental analysis. The  $^{13}C\{^1H\}$  NMR spectrum is notable for the carbenic signal at  $\delta$  180.7 that shows coupling to both  $^{109}Ag$  ( $^1J_{AgC} = 211$  Hz) and  $^{107}Ag$  ( $^1J_{AgC} = 183$  Hz); the chemical shift and relative magnitudes of these coupling constants are in good agreement with literature values.<sup>16a</sup> Interrogation of single crystals of **4a** by X-ray diffraction provides further evidence to the


mononuclear formulation of **4a** in solution, revealing a distorted linear geometry of the silver cation [ $C2-Ag1-C8 = 171.00$  ( $14^\circ$ ) and essentially equivalent  $Ag-C$  bond lengths ( $Ag1-C2, 2.085(4)$ ;  $Ag1-C8, 2.083(4)$ ; Fig. 3). The biscarbene silver complex of  $I^1Pr_2Me_2$  bearing the tetrafluoroborate counter anion [ $Ag(I^1Pr_2Me_2)_2$ ][ $BF_4$ ] **G** has previously been prepared,<sup>17</sup> however, for comparison the analogue bearing the [ $BAR^F_4$ ] $^-$  counter anion **4b** was generated *in situ* through reaction of  $Ag[OTf]$ , Na[ $BAR^F_4$ ] and 2 equiv.  $I^1Pr_2Me_2$  in 1,2- $C_6H_4F_2$ . The solid-state structure of **4b** is notable for a significantly more orthogonal orientation of the NHC ligands in comparison to **4a** and **G** [*e.g.*  $|N6-C2-C8-N12| = 3.7(5)^\circ$ , **4a**;  $|N3-C2-C15-N19| = 77.0(5)^\circ$ , **4b**;  $|N-C-C-N| = 20.6(6)^\circ$ , **G**]. The near coplanar disposition of the NHC donors in **4a** is fully in line with expectation, and readily attributed to the calix[4]arene scaffold [ $\Delta\theta_{CALIX} = -96.4(2)^\circ$ ], while the conformational differences in **4b/G** are presumably attributed to crystal packing effects, induced by disparate anion sizes, and enabled through low-energy  $Ag-NHC$  bond rotation. The  $Ag-C$  bond lengths are all within experimental error [ $2.085(4)/2.083(4)$  Å, **4a**;  $2.093(4)/2.092(4)$  Å, **4b**;  $2.078(11)$  Å, **G**], although we note an apparent trend of bond length contraction for **4a** in comparison to **4b** and that this parameter was not determined with high precision for **G**.

Silver complex **4a** acts as an effective carbene transfer agent, resulting in the formation of dinuclear complexes **5a** and **6a** bearing both  $\mu^2-1$  and  $\mu^2-Cl$  ligands on reaction with 1 equiv. of [ $Rh(COD)Cl$ ] $_2$  and [ $Rh(CO)_2Cl$ ] $_2$ , respectively, in 1,2- $C_6H_4F_2$  – established by NMR spectroscopy and ESI-MS. The reaction stoichiometries were maintained when using 0.5 equiv. of rhodium dimer instead, indicating selective formation **5a** and **6a**. Both dinuclear products were obtained in moderate isolated yields (63% and 59% respectively) and were difficult to fully purify, due to limited solution stability. Aided by comparison to **2a/3a** and supported through preparation of direct  $I^1Pr_2Me_2$  analogues (*vide infra*), the formulation of the structures of **5a/6a** was achieved through a combination of  $^1H$ ,  $^{13}C$  NMR and IR spectroscopy, ESI-MS and in the case of **5b** a low resolution X-ray structure (Fig. 4). The ESI-MS in particular evidenced formation of these dinuclear monocationic species, with parent cation signals at 1209.3986 (calcd 1209.3973) and




Scheme 3 Preparation and transmetalation reactions of silver NHC complexes.





**Fig. 3** Solid-state structures of **4a** and **4b**. Thermal ellipsoids for selected atoms drawn at the 30% probability level; minor disordered components (four O<sup>*n*</sup>Pr groups in **4a**), hydrogen atoms and anions omitted for clarity. Selected bond lengths (Å) and angles (°): **4a**: Ag1–C2, 2.085(4); Ag1–C8, 2.083(4); C2–Ag1–C8, 171.00(14); ∠Mpln(C14–C19,O42)–Mpln(C28–C33,O50), 1.01(8); ∠Mpln(C21–C26,O46)–Mpln(C35–C40,O54), 97.44(10); **4b**: Ag1–C2, 2.093(4); Ag1–C15, 2.092(4); C2–Ag1–C15, 176.81(15).




**Fig. 4** Solid-state structure of **6a** (ball and stick, poor quality data). Minor disordered component (CO), hydrogen atoms and anion omitted for clarity. Selected bond lengths (Å) and angles (°): Rh1–Cl3, 2.353(5); Rh2–Cl3, 2.360(5); Rh1...Rh2, 3.861(3); Rh1–Cl3–Rh2, 110.0(3); ∠Mpln(C24–C29,O52)–Mpln(C38–C43,O60), 9.7(3); ∠Mpln(C31–C36,O56)–Mpln(C45–C50,O64), 92.8(4).

1105.1680 (calcd 1105.1891)  $m/z$ , respectively for **5a** and **6a**, with correct isotope patterns and integer mass spacing. Moreover the cation : [BAR<sup>F</sup><sub>4</sub>] ratio was verified by integration of <sup>1</sup>H NMR data. In both cases, single carbene resonances [ $\delta$  176.9 (<sup>1</sup> $J_{\text{RhC}} = 50$  Hz), **5a**; 168.1 (<sup>1</sup> $J_{\text{RhC}} = 43$  Hz), **6a**] with very similar chemical shifts and <sup>1</sup> $J_{\text{RhC}}$  coupling constants to the respective neutral analogues [ $\delta$  180.4 (<sup>1</sup> $J_{\text{RhC}} = 49$  Hz), **2a**; 171.5 (<sup>1</sup> $J_{\text{RhC}} = 44$  Hz), **3a**], alongside <sup>103</sup>Rh coupled alkene and carbonyl signals, were observed by <sup>13</sup>C NMR spectroscopy. For **6a** both carbonyl stretching bands are perturbed (as expected) to higher frequency relative to neutral **3a** [ $\nu(\text{CO}) = 2083, 2016$ , **6a**; 2071, 2002 cm<sup>-1</sup>, **3a**]. Bond connectivity and conformational features


of **6a** were established through X-ray diffraction, using a poor quality crystalline sample [ $R_1 = 0.2744$ ,  $I \geq 2\sigma(I)$ ]. The data nevertheless can affirm the structural formulation, with a reduced pinching of calix[4]arene core [ $\Delta\theta_{\text{CALIX}} = -83.1(7)^\circ$ ] relative to **2a** [ $\Delta\theta_{\text{CALIX}} = -98.41(12)^\circ$ ] and **4a** [ $\Delta\theta_{\text{CALIX}} = -96.4(2)^\circ$ ].

Starting from the known precursors [Rh(<sup>1</sup>Pr<sub>2</sub>Me<sub>2</sub>)(COD)Cl] and [Rh(<sup>1</sup>Pr<sub>2</sub>Me<sub>2</sub>)(CO)<sub>2</sub>Cl], the new  $\mu^2$ -Cl bridged dinuclear complexes **5b** and **6b** were readily prepared by partial halide extraction using 0.5 equiv. of Na[BAR<sup>F</sup><sub>4</sub>] in CH<sub>2</sub>Cl<sub>2</sub> (Scheme 4). These structurally simple and fully characterised species (solution and solid-state, Fig. 5) help verify the formulation of **5a** and **6a**, with excellent agreement of the related spectroscopic data e.g. carbene <sup>13</sup>C signals of **5** [ $\delta$ 176.9 (<sup>1</sup> $J_{\text{RhC}} = 50$  Hz), **5a**; 175.6 (<sup>1</sup> $J_{\text{RhC}} = 50$  Hz), **5b**] and carbonyl stretching bands of **6** [ $\nu(\text{CO}) = 2083, 2016$ , **6a**; 2090, 2019 cm<sup>-1</sup>, **6b**] – see Experimental section for full details. Although iridium NHC and rhodium phosphine examples have been reported, there are no proceeding crystallographically characterised examples of rhodium NHC complexes featuring a single otherwise unsupported bridging halogen atom to the best of our knowledge.<sup>18</sup> Conformational differences, associated with the relative orientation of the NHC ligands about the Rh–Cl–Rh bridge, are evident when comparing the solid-state structures of **6a** (*anti*) **5b** (*syn*) **6b** (*anti*); <sup>1</sup>H and <sup>13</sup>C NMR data for **5a** and **6a** are most consistent with C<sub>2</sub> symmetry and *anti*-configurations in solution. Contrasting reactions of **4a** and **4b**, the calix[4]arene scaffold promotes the selective formation of dinuclear com-



**Scheme 4** Preparation of dinuclear complexes **5b** and **6b**.





**Fig. 5** Solid-state structures of **5b** and **6b**. Thermal ellipsoids drawn at the 50% probability level; minor disordered components (two <sup>i</sup>Pr groups in **6b**), hydrogen atoms, solvent (**6a**), and anions omitted for clarity. Selected bond lengths (Å) and angles (°): **5b**: Rh1–Cl3, 2.3988(9); Rh1–Cnt(C4,C5), 2.092(5); Rh1–Cnt(C8,C9), 1.974(4); Rh1–C20, 2.025(3); Rh2–Cl3, 2.4067(9); Rh2–Cnt(C12,C13), 2.101(4); Rh2–Cnt(C16,C17), 1.972(4); Rh2–C33, 2.022(3); Rh1–Cl3–Rh2, 144.13(4); **6b**: Rh1–Cl3, 2.4045(9); Rh1–C4, 1.915(4); Rh1–C6, 1.833(4); Rh1–C22, 2.069(3); Rh2–Cl3, 2.3987(9); Rh2–C8, 1.920(4); Rh2–C10, 1.817(4); Rh2–C25, 2.069(3); Rh1–Cl3–Rh2, 122.26(4).

plexes. For instance, when **4b** is reacted with 1 equiv. of  $[\text{Rh}(\text{COD})\text{Cl}]_2$  or  $[\text{Rh}(\text{CO})_2\text{Cl}]_2$  in 1,2- $\text{C}_6\text{H}_4\text{F}_2$  mixtures of **5b**/*cis*- $[\text{Rh}(\text{i}^i\text{Pr}_2\text{Me}_2)_2(\text{COD})][\text{BAR}^{\text{F}}_4]$  **7** (2 : 1) and **6b**/*cis*- $[\text{Rh}(\text{i}^i\text{Pr}_2\text{Me}_2)_2(\text{CO})_2][\text{BAR}^{\text{F}}_4]$  **8** (5 : 2) are the organometallic species produced as determined by <sup>1</sup>H NMR spectroscopy (Scheme 3) – with the structures of **7** and **8** verified by independent synthesis and full characterisation, including in the solid-state by X-ray diffraction (see experimental for full details).

## Summary

Using both free carbene and transmetalation methodologies the coordination chemistry of bis(imidazolium) pro-ligand 1·2HI with rhodium(i) dimers  $[\text{Rh}(\text{COD})\text{Cl}]_2$  and  $[\text{Rh}(\text{CO})_2\text{Cl}]_2$  has been investigated, culminating in the isolation of neutral and cationic dinuclear complexes where the calix[4]arene based-NHC is bound in a  $\mu^2$ -coordination mode. These dinuclear complexes have been well characterised in solution using NMR spectroscopy, IR spectroscopy (CO derivatives) and ESI-MS (cationic complexes), and their structural formulation corroborated through excellent agreement of these data with that associated with simpler model complexes containing instead  $\text{i}^i\text{Pr}_2\text{Me}_2$ . Structures determined through X-ray diffraction highlight the flexibility of the calix[4]arene ligand scaffold, which undergoes significant conformational change driven by charge repulsion (bis-cationic 1·2HI),  $\pi$ -stacking of the imidazolylidene rings (**2a**), *trans*-coordination to silver (**4a**), or presence of a bridging  $\mu^2$ -Cl ligand (**6a**).

## Experimental

### General considerations

All manipulations were performed under an atmosphere of argon, using Schlenk and glove box techniques unless otherwise

stated. Glassware was oven dried at 150 °C overnight and flamed under vacuum prior to use. Anhydrous  $\text{CH}_2\text{Cl}_2$ ,  $\text{Et}_2\text{O}$ , and pentane (<0.005%  $\text{H}_2\text{O}$ ) were purchased from ACROS or Aldrich and freeze–pump–thaw degassed three times before being placed under argon. THF was dried over sodium/benzophenone, vacuum distilled, and freeze–pump–thaw degassed three times before being placed under argon. 1,2- $\text{C}_6\text{H}_4\text{F}_2$  was stirred over neutral alumina, filtered, dried over  $\text{CaH}_2$ , vacuum distilled, and freeze–pump–thaw degassed three times before being placed under argon over 3 Å molecular sieves.  $\text{CD}_2\text{Cl}_2$  was dried over  $\text{CaH}_2$ , vacuum distilled, and freeze–pump–thaw degassed three times before being placed under argon.  $\text{C}_6\text{D}_6$  was dried over Na, vacuum distilled, and freeze–pump–thaw degassed three times before being placed under argon.  $d_8$ -THF was dried over 3 Å molecular sieves and freeze–pump–thaw degassed three times before being placed under argon. 5,17-bis(imidazolium)-25,26,27,28-tetrapropoxycalix[4]arene (**F**),<sup>12</sup>  $\text{i}^i\text{Pr}_2\text{Me}_2$ ,<sup>10</sup>  $[\text{Rh}(\text{COD})\text{Cl}]_2$ ,<sup>19</sup>  $[\text{Rh}(\text{CO})_2\text{Cl}]_2$ ,<sup>20</sup>  $\text{Na}[\text{BAR}^{\text{F}}_4]$ ,<sup>21</sup>  $[\text{Rh}(\text{i}^i\text{Pr}_2\text{Me}_2)(\text{COD})\text{Cl}]$ ,<sup>22</sup> and *cis*- $[\text{Rh}(\text{i}^i\text{Pr}_2\text{Me}_2)(\text{CO})_2\text{Cl}]$ <sup>22</sup> were synthesised using literature protocols. All other solvents and reagents are commercial products and were used as received. NMR spectra were recorded on Bruker AV spectrometers at 298 K unless otherwise stated. <sup>1</sup>H NMR spectra recorded in 1,2- $\text{C}_6\text{H}_4\text{F}_2$  were referenced using the highest intensity peak of the highest ( $\delta$  6.865) frequency fluoroarene multiplet. <sup>13</sup>C{<sup>1</sup>H} NMR spectra recorded in 1,2- $\text{C}_6\text{H}_4\text{F}_2$  were referenced using an internal sealed capillary of  $\text{C}_6\text{D}_6$ . Chemical shifts are quoted in ppm and coupling constants in Hz. IR spectra were recorded on a PerkinElmer Spectrum One FT-IR spectrometer at 293 K. ESI-MS analyses were recorded on Bruker Maxis Impact instrument. Microanalyses were performed by Stephen Boyer at London Metropolitan University.

### Preparation of 1·2HI

A solution of **F** (1.00 g, 1.38 mmol) was stirred with iodomethane (0.84 mL, 13.8 mmol) in THF (30 mL) at 70 °C for



14 hours. The product was isolated by filtration following addition of Et<sub>2</sub>O (ca. 20 mL), washed with Et<sub>2</sub>O (2 × 20 mL) and dried *in vacuo*. Yield = 1.17 g (84%, fine off-white powder).

<sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz): δ 9.20 (br, 2H, NCHN), 8.04 (t, <sup>3</sup>J<sub>HH</sub> = 1.8, 2H, imid.), 7.23 (d, <sup>3</sup>J<sub>HH</sub> = 7.5, 4H, Ar), 7.05 (t, <sup>3</sup>J<sub>HH</sub> = 7.5, 2H, Ar), 6.72 (t, <sup>3</sup>J<sub>HH</sub> = 1.8, 2H, imid.), 6.61 (s, 4H, Ar), 4.54 (d, <sup>2</sup>J<sub>HH</sub> = 13.5, 4H, ArCH<sub>2</sub>Ar), 4.17 (s, 6H, NCH<sub>3</sub>), 4.03–4.09 (m, 4H, OCH<sub>2</sub>), 3.74 (t, <sup>3</sup>J<sub>HH</sub> = 6.8, 4H, OCH<sub>2</sub>), 3.28 (d, <sup>2</sup>J<sub>HH</sub> = 13.5, 4H, ArCH<sub>2</sub>Ar), 1.87–2.06 (m, 8H, CH<sub>2</sub>CH<sub>3</sub>), 1.12 (t, <sup>3</sup>J<sub>HH</sub> = 7.4, 6H, CH<sub>2</sub>CH<sub>3</sub>), 0.93 (t, <sup>3</sup>J<sub>HH</sub> = 7.5, 6H, CH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz): δ 157.5 (s, COCH<sub>2</sub>), 157.3 (s, COCH<sub>2</sub>), 137.7 (s, Ar{CCH<sub>2</sub>}), 135.7 (s, Ar{CCH<sub>2</sub>}), 134.9 (s, NCHN), 130.2 (s, Ar), 129.2 (s, Ar{CN}), 125.6 (s, imid.), 124.4 (s, Ar), 120.8 (s, Ar), 119.9 (s, imid.), 78.1 (s, OCH<sub>2</sub>), 77.4 (s, OCH<sub>2</sub>), 37.8 (s, NCH<sub>3</sub>), 31.4 (s, ArCH<sub>2</sub>Ar), 23.9 (s, CH<sub>2</sub>CH<sub>3</sub>), 23.5 (s, CH<sub>2</sub>CH<sub>3</sub>), 10.9 (s, CH<sub>2</sub>CH<sub>3</sub>), 10.2 (s, CH<sub>2</sub>CH<sub>3</sub>). ESI-MS (CH<sub>3</sub>CN, 180 °C, 3 kV) positive ion: 377.2220 *m/z*, [M]<sup>2+</sup> (calcd 377.2224 *m/z*). Anal. Calcd For C<sub>48</sub>H<sub>58</sub>I<sub>2</sub>N<sub>4</sub>O<sub>4</sub> (1008.81 g mol<sup>-1</sup>): C, 57.13; H, 5.80; N, 5.55. Found: C, 56.88; H, 6.00; N, 5.55.

### Deprotonation of 1-2HI

A suspension of 1-2HI (10.2 mg, 0.0101 mmol) and K[O<sup>t</sup>Bu] (3.1 mg, 0.0276 mmol) in d<sub>8</sub>-THF (0.5 mL) was agitated and sonicated for several minutes inside a sealed J. Young's NMR tube. Analysis by NMR spectroscopy indicated quantitative formation of **1** with the concomitant formation of <sup>t</sup>BuOH (δ<sub>H</sub> 5.33, OH; 1.15, CH<sub>3</sub>; δ<sub>C</sub> 68.1, CCH<sub>3</sub>; 31.6, CH<sub>3</sub>). The reaction was repeated in C<sub>6</sub>D<sub>6</sub> with the same outcome. The <sup>1</sup>H NMR spectra remained unchanged on standing at 293 K for 24 h in both cases.

<sup>1</sup>H NMR (d<sub>8</sub>-THF, 500 MHz): δ 7.41 (s, 4H, Ar), 7.24 (d, <sup>3</sup>J<sub>HH</sub> = 1.6, 2H, imid.), 6.94 (d, <sup>3</sup>J<sub>HH</sub> = 1.6, 2H, imid.), 6.40 (d, <sup>3</sup>J<sub>HH</sub> = 7.5, 4H, Ar), 6.31 (app t, 2H, *J* = 8, Ar), 4.51 (d, <sup>2</sup>J<sub>HH</sub> = 13.1, 4H, ArCH<sub>2</sub>Ar), 4.00–4.04 (m, 4H, OCH<sub>2</sub>), 3.76–3.79 (m, 4H, OCH<sub>2</sub>), 3.76 (s, 6H, NCH<sub>3</sub>), 3.20 (d, <sup>2</sup>J<sub>HH</sub> = 13.1, 4H, ArCH<sub>2</sub>Ar), 1.99–2.07 (m, 4H, CH<sub>2</sub>CH<sub>3</sub>), 1.92–1.99 (m, 4H, CH<sub>2</sub>CH<sub>3</sub>), 1.10 (t, <sup>3</sup>J<sub>HH</sub> = 7.4, 6H, CH<sub>2</sub>CH<sub>3</sub>), 0.98 (t, <sup>3</sup>J<sub>HH</sub> = 7.5, 6H, CH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (d<sub>8</sub>-THF, 126 MHz): δ 216.0 (s, NCN), 156.7 (s, COCH<sub>2</sub>), 156.3 (s, COCH<sub>2</sub>), 137.9 (s, Ar{CN}), 137.6 (s, Ar{CCH<sub>2</sub>}), 134.5 (s, Ar{CCH<sub>2</sub>}), 128.9 (s, Ar), 123.1 (s, Ar), 121.6 (s, Ar), 121.1 (s, imid.), 118.1 (s, imid.), 77.9 (s, OCH<sub>2</sub>), 77.7 (s, OCH<sub>2</sub>), 38.3 (s, NCH<sub>3</sub>), 32.0 (s, ArCH<sub>2</sub>Ar), 24.5 (s, CH<sub>2</sub>CH<sub>3</sub>), 24.2 (s, CH<sub>2</sub>CH<sub>3</sub>), 11.2 (s, CH<sub>2</sub>CH<sub>3</sub>), 10.7 (s, CH<sub>2</sub>CH<sub>3</sub>). <sup>1</sup>H NMR (C<sub>6</sub>D<sub>6</sub>, 500 MHz): δ 7.40 (s, 4H, Ar), 6.74 (d, <sup>3</sup>J<sub>HH</sub> = 7.5, 4H, Ar), 6.71 (br, 2H, imid.), 6.61 (t, <sup>3</sup>J<sub>HH</sub> = 7.5, 2H, Ar), 6.18 (br, 2H, imid.), 4.53 (d, <sup>2</sup>J<sub>HH</sub> = 13.2, 4H, ArCH<sub>2</sub>Ar), 3.87 (t, <sup>3</sup>J<sub>HH</sub> = 7.6, 4H, OCH<sub>2</sub>), 3.76 (t, <sup>3</sup>J<sub>HH</sub> = 7.4, 4H, OCH<sub>2</sub>), 3.42 (s, 6H, NCH<sub>3</sub>), 3.17 (d, <sup>2</sup>J<sub>HH</sub> = 13.3, 4H, ArCH<sub>2</sub>Ar), 1.84–1.95 (m, 8H, CH<sub>2</sub>CH<sub>3</sub>), 0.93 (app. t, *J* = 7, 12H, CH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (C<sub>6</sub>D<sub>6</sub>, 126 MHz): δ 213.2 (s, NCN), 156.7 (s, COCH<sub>2</sub>), 155.5 (s, COCH<sub>2</sub>), 137.1 (s, Ar{CN}), 136.4 (s, Ar{CCH<sub>2</sub>}), 134.7 (s, Ar{CCH<sub>2</sub>}), 128.8 (s, Ar), 123.0 (s, Ar), 121.5 (s, Ar), 120.1 (s, imid.), 117.8 (s, imid.), 77.1 (s, OCH<sub>2</sub>), 77.0 (s, OCH<sub>2</sub>), 37.8 (s, NCH<sub>3</sub>), 31.6 (s, ArCH<sub>2</sub>Ar), 23.7

(s, CH<sub>2</sub>CH<sub>3</sub>), 23.6 (s, CH<sub>2</sub>CH<sub>3</sub>), 10.6 (s, CH<sub>2</sub>CH<sub>3</sub>), 10.5 (s, CH<sub>2</sub>CH<sub>3</sub>).

### Preparation of 2a

A solution of 1-2HI (99.7 mg, 0.0987 mmol) and K[O<sup>t</sup>Bu] (27.8 mg, 0.248 mmol) was stirred in THF (10 mL) for 1 hour then added to a flask charged with [Rh(COD)Cl]<sub>2</sub> (51.6 mg, 0.105 mmol) and KI (165.1 mg, 1.42 mmol). After a further hour the volatiles were removed *in vacuo*. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 10 mL) and purified over alumina (1 : 1 EtOAc/CH<sub>2</sub>Cl<sub>2</sub>, Air). Yield = 75.5 mg (53%, yellow powder).

<sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz): δ 7.95 (d, <sup>4</sup>J<sub>HH</sub> = 2.8, 2H, Ar), 7.29–7.39 (m, 2H, Ar), 7.04–7.14 (m, 2H, Ar), 6.97 (t, <sup>3</sup>J<sub>HH</sub> = 7.4, 2H, Ar), 6.44 (d, <sup>3</sup>J<sub>HH</sub> = 2.0, 2H, imid.), 6.19 (d, <sup>3</sup>J<sub>HH</sub> = 2.0, 2H, imid.), 5.92 (d, <sup>4</sup>J<sub>HH</sub> = 2.8, 2H, Ar), 5.24–5.29 (m, 2H, COD{CH}), 4.92–5.09 (m, 2H, COD{CH}), 4.62 (d, <sup>2</sup>J<sub>HH</sub> = 13.3, 2H, ArCH<sub>2</sub>Ar), 4.50 (d, <sup>2</sup>J<sub>HH</sub> = 13.5, 2H, ArCH<sub>2</sub>Ar), 3.99–4.18 (m, 4H, OCH<sub>2</sub>), 3.85 (s, 6H, NCH<sub>3</sub>), 3.65–3.82 (m, 4H, OCH<sub>2</sub>), 3.38 (d, <sup>2</sup>J<sub>HH</sub> = 13.4, 2H, ArCH<sub>2</sub>Ar), 3.21–3.26 (m, 2H, COD{CH}), 3.19 (d, <sup>2</sup>J<sub>HH</sub> = 13.7, 2H, ArCH<sub>2</sub>Ar), 2.29–2.39 (m, 2H, COD{CH}), 2.09–2.29 (m, 6H, COD{CH<sub>2</sub>}), 1.97–2.09 (m, 4H, CH<sub>2</sub>CH<sub>3</sub>), 1.83–1.97 (m, 6H, CH<sub>2</sub>CH<sub>3</sub> + COD{CH<sub>2</sub>}), 1.58–1.79 (m, 4H, COD{CH<sub>2</sub>}), 1.27–1.46 (m, 4H, COD{CH<sub>2</sub>}), 1.15 (t, <sup>3</sup>J<sub>HH</sub> = 7.4, 6H, CH<sub>2</sub>CH<sub>3</sub>), 0.95 (t, <sup>3</sup>J<sub>HH</sub> = 7.5, 6H, CH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz): δ 180.4 (d, <sup>1</sup>J<sub>RhC</sub> = 49, NCN), 158.2 (s, COCH<sub>2</sub>), 155.0 (s, COCH<sub>2</sub>), 137.0 (s, Ar{CCH<sub>2</sub>}), 136.9 (s, Ar{CCH<sub>2</sub>}), 134.9 (s, Ar{C}), 134.7 (s, Ar{C}), 134.3 (s, Ar{C}), 131.5 (s, Ar), 129.6 (s, Ar), 123.6 (s, Ar), 123.4 (s, imid.), 122.9 (s, Ar), 122.5 (s, imid.), 122.5 (s, Ar), 95.0 (d, <sup>1</sup>J<sub>RhC</sub> = 7, COD{CH}), 95.0 (d, <sup>1</sup>J<sub>RhC</sub> = 7, COD{CH}), 77.7 (s, OCH<sub>2</sub>), 77.3 (s, OCH<sub>2</sub>), 71.4 (d, <sup>1</sup>J<sub>RhC</sub> = 14, 2 × COD{CH}), 39.1 (s, NCH<sub>3</sub>), 33.9 (s, COD{CH<sub>2</sub>}), 31.7 (s, CH<sub>2</sub>), 31.4 (s, CH<sub>2</sub>), 31.0 (s, CH<sub>2</sub>), 30.7 (s, CH<sub>2</sub>), 29.2 (s, COD{CH<sub>2</sub>}), 23.8 (s, CH<sub>2</sub>CH<sub>3</sub>), 23.4 (s, CH<sub>2</sub>CH<sub>3</sub>), 11.3 (s, CH<sub>2</sub>CH<sub>3</sub>), 10.3 (s, CH<sub>2</sub>CH<sub>3</sub>). Anal. Calcd For C<sub>64</sub>H<sub>80</sub>I<sub>2</sub>N<sub>4</sub>O<sub>4</sub> (1428.24 g mol<sup>-1</sup>): C, 53.79; H, 5.64; N, 3.92. Found: C, 53.71; H, 5.75; N, 4.04.

### Preparation of 2b

A solution of <sup>1</sup>Pr<sub>2</sub>Me<sub>2</sub> (61.2 mg, 0.336 mmol), [Rh(COD)Cl]<sub>2</sub> (166.1 mg, 0.337 mmol) and KI (1072.2 mg, 6.46 mmol) in THF (10 mL) was stirred for 1 hour. The volatiles were removed *in vacuo* and the product obtained after purification over silica (CH<sub>2</sub>Cl<sub>2</sub>, Air) and subsequent recrystallisation from CH<sub>2</sub>Cl<sub>2</sub>/pentane. Yield = 55.0 mg (31%, yellow crystals).

<sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 500 MHz): δ 5.97 (sept, <sup>3</sup>J<sub>HH</sub> = 7.1, 2H, NCH), 5.03–5.09 (m, 2H, COD{CH}), 3.50–3.57 (m, 2H, COD{CH}), 2.26–2.36 (m, 4H, COD{CH<sub>2</sub>}), 2.16 (s, 6H, CCH<sub>3</sub>), 1.87–1.98 (m, 2H, COD{CH<sub>2</sub>}), 1.73–1.83 (m, 2H, COD{CH<sub>2</sub>}), 1.56 (d, <sup>3</sup>J<sub>HH</sub> = 7.1, 6H, CHCH<sub>3</sub>), 1.50 (d, <sup>3</sup>J<sub>HH</sub> = 7.1, 6H, CHCH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>, 126 MHz): δ 178.4 (d, <sup>1</sup>J<sub>RhC</sub> = 49, NCN), 126.0 (s, CCH<sub>3</sub>), 95.2 (d, <sup>1</sup>J<sub>RhC</sub> = 7, COD{CH}), 71.5 (d, <sup>1</sup>J<sub>RhC</sub> = 14, COD{CH}), 53.7 (s, NCH), 32.8 (s, COD{CH<sub>2</sub>}), 30.0 (s, COD{CH<sub>2</sub>}), 22.4 (s, CHCH<sub>3</sub>), 21.4 (s, CHCH<sub>3</sub>), 10.7 (s, CCH<sub>3</sub>). Anal. Calcd for C<sub>19</sub>H<sub>32</sub>I<sub>2</sub>N<sub>2</sub>Rh (518.29 g mol<sup>-1</sup>): C, 44.03; H, 6.22; N, 5.41. Found: C, 44.11; H, 6.14; N, 5.47.



### Preparation of 3a

**Method A:** A solution of 1·2HI (102.1 mg, 0.101 mmol) and K[O<sup>t</sup>Bu] (28.9 mg, 0.258 mmol) was stirred in THF (10 mL) for 1 hour then added to a flask charged with [Rh(CO)<sub>2</sub>Cl]<sub>2</sub> (40.7 mg, 0.105 mmol) and KI (165.4 mg, 0.996 mmol). After a further hour the volatiles were removed *in vacuo*. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 10 mL) and purified over alumina (1 : 1 Et<sub>2</sub>O/CH<sub>2</sub>Cl<sub>2</sub>, Air). Yield = 22.4 mg (17%, yellow powder). **Method B:** A solution of 2a (121.2 mg, 0.0848 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was stirred under CO (1 atm) for 12 hours, resulting in a colour change from bright to pale yellow. The mixture was dried *in vacuo* and washed with pentane (3 × 5 mL). Yield = 42.1 mg (37%, yellow powder).

<sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 500 MHz): δ 7.26 (s, 2H, Ar), 7.02 (br, 4H, Ar), 6.82 (t, <sup>3</sup>J<sub>HH</sub> = 7.4, 2H, Ar), 6.77 (s, 2H, imid.), 6.46 (s, 2H, imid.), 6.41 (s, 2H, Ar), 4.51 (d, <sup>2</sup>J<sub>HH</sub> = 13.3, 2H, ArCH<sub>2</sub>Ar), 4.48 (d, <sup>2</sup>J<sub>HH</sub> = 13.6, 2H, ArCH<sub>2</sub>Ar), 3.80–4.09 (m, 8H, OCH<sub>2</sub>), 3.77 (s, 6H, NCH<sub>3</sub>), 3.24 (d, <sup>2</sup>J<sub>HH</sub> = 14.1, 2H, ArCH<sub>2</sub>Ar), 3.22 (d, <sup>2</sup>J<sub>HH</sub> = 14.1, 2H, ArCH<sub>2</sub>Ar), 1.79–2.16 (m, 8H, CH<sub>2</sub>CH<sub>3</sub>), 1.03–1.13 (m, 6H, CH<sub>2</sub>CH<sub>3</sub>), 0.92–1.03 (m, 6H, CH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>, 126 MHz): δ 188.4 (d, <sup>1</sup>J<sub>RhC</sub> = 54, CO), 181.6 (d, <sup>1</sup>J<sub>RhC</sub> = 78, CO), 171.5 (d, <sup>1</sup>J<sub>RhC</sub> = 44, NCN), 157.5 (s, COCH<sub>2</sub>), 156.3 (s, COCH<sub>2</sub>), 136.2, 136.1, 135.9, 135.6, 130.6, 129.4, 123.8, 123.4, 123.2, 122.8, 77.8 (OCH<sub>2</sub>), 77.4 (OCH<sub>2</sub>), 40.0 (s, NCH<sub>3</sub>), 31.5 (br, ArCH<sub>2</sub>Ar), 24.0 (CH<sub>2</sub>CH<sub>3</sub>), 23.7 (CH<sub>2</sub>CH<sub>3</sub>), 11.0 (s, CH<sub>2</sub>CH<sub>3</sub>), 10.4 (s, CH<sub>2</sub>CH<sub>3</sub>). Not all signals were unambiguously identified. IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>): ν(CO) 2071, 2002. Anal. Calcd for C<sub>52</sub>H<sub>56</sub>I<sub>2</sub>N<sub>4</sub>O<sub>8</sub>Rh<sub>2</sub> (1324.02 g mol<sup>-1</sup>): C, 47.15; H, 4.26; N, 4.23. Found: C, 46.91; H, 4.12; N, 4.25.

### Preparation of 3b

A solution of 2b (40.1 mg, 0.0774 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was placed under an atmosphere of CO (1 atm) for 2 hours. The volatiles were removed *in vacuo* to afford the product, which was washed with pentane (3 × 10 mL) and dried thoroughly under vacuum. Yield = 21.4 mg (59%, fine yellow powder).

<sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 500 MHz): δ 5.26 (sept, <sup>3</sup>J<sub>HH</sub> = 7.1, 2H, NCH), 2.22 (s, 6H, CCH<sub>3</sub>), 1.501 (d, <sup>3</sup>J<sub>HH</sub> = 7.1, 6H, CHCH<sub>3</sub>), 1.496 (d, <sup>3</sup>J<sub>HH</sub> = 2.7, 6H, CHCH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>, 126 MHz): δ 188.7 (d, <sup>1</sup>J<sub>RhC</sub> = 53, CO), 182.7 (d, <sup>1</sup>J<sub>RhC</sub> = 78, CO), 166.8 (d, <sup>1</sup>J<sub>RhC</sub> = 41, NCN), 127.2 (s, CCH<sub>3</sub>), 54.3 (s, CHCH<sub>3</sub>), 22.2 (s, CHCH<sub>3</sub>), 21.1 (s, CHCH<sub>3</sub>), 10.7 (s, CCH<sub>3</sub>). IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>): ν(CO) 2072, 1998. Anal. Calcd for C<sub>13</sub>H<sub>20</sub>I<sub>2</sub>N<sub>2</sub>O<sub>2</sub>Rh (466.12 g mol<sup>-1</sup>): C, 33.50; H, 4.33; N, 6.01. Found: C, 33.41; H, 4.25; N, 6.03.

### Preparation of 4a

A suspension of 1·2HI (79.5 mg, 0.0788 mmol), Ag<sub>2</sub>O (20.0 mg, 0.0862 mmol) and Na[BAR<sup>F</sup><sub>4</sub>] (69.0 mg, 0.0778 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was sonicated periodically over two hours. The solution was filtered and the solvent was removed *in vacuo* to afford the product. Yield = 100.0 mg (73%, white crystals).

<sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>): δ 7.72–7.76 (m, 8H, Ar<sup>F</sup>), 7.57 (br, 4H, Ar<sup>F</sup>), 7.10 (d, <sup>3</sup>J<sub>HH</sub> = 7.4, 4H, Ar), 6.92 (d, <sup>3</sup>J<sub>HH</sub> = 1.7, 2H, imid.), 6.85 (t, <sup>3</sup>J<sub>HH</sub> = 7.5, 2H, Ar), 6.81 (d, <sup>3</sup>J<sub>HH</sub> = 1.7, 2H, imid.), 6.40 (s, 4H, Ar), 4.57 (d, <sup>2</sup>J<sub>HH</sub> = 12.8, 4H, ArCH<sub>2</sub>Ar), 4.10–4.22 (m, 4H, OCH<sub>2</sub>), 3.80 (s, 6H, NCH<sub>3</sub>), 3.74 (t, <sup>3</sup>J<sub>HH</sub> = 7.1, 4H, OCH<sub>2</sub>), 3.24 (d, <sup>2</sup>J<sub>HH</sub> = 12.8, 4H, ArCH<sub>2</sub>Ar), 2.10–2.21 (m, 4H, CH<sub>2</sub>CH<sub>3</sub>), 1.99 (app. sex., J = 7, 4H, CH<sub>2</sub>CH<sub>3</sub>), 1.12 (t, <sup>3</sup>J<sub>HH</sub> = 7.4, 6H, CH<sub>2</sub>CH<sub>3</sub>), 0.98 (t, <sup>3</sup>J<sub>HH</sub> = 7.5, 6H, CH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz): δ 180.7 (two coincident d, <sup>1</sup>J<sub>109AgC</sub> = 211, <sup>1</sup>J<sub>107AgC</sub> = 183, NCN), 162.3 (q, <sup>1</sup>J<sub>BC</sub> = 50.5, Ar<sup>F</sup>), 157.8 (COCH<sub>2</sub>), 156.7 (s, COCH<sub>2</sub>), 136.5 (s, 2 × Ar{C}), 135.4 (s, Ar<sup>F</sup>), 134.3 (s, Ar{C}), 129.4 (qq, <sup>2</sup>J<sub>FC</sub> = 32, <sup>3</sup>J<sub>BC</sub> = 3, Ar<sup>F</sup>), 129.3 (s, Ar), 118.0 (sept, <sup>3</sup>J<sub>FC</sub> = 4, Ar<sup>F</sup>), 126.4 (s, Ar), 125.2 (q, <sup>1</sup>J<sub>FC</sub> = 272, Ar<sup>F</sup>), 124.7 (d, <sup>3</sup>J<sub>AgC</sub> = 6, imid.), 123.4 (s, Ar), 121.9 (d, <sup>3</sup>J<sub>AgC</sub> = 6, imid.), 118.0 (sept, <sup>3</sup>J<sub>FC</sub> = 4, Ar<sup>F</sup>), 78.7 (s, OCH<sub>2</sub>), 77.2 (s, OCH<sub>2</sub>), 38.8 (d, <sup>3</sup>J<sub>AgC</sub> = 3, NCH<sub>3</sub>), 31.4 (s, ArCH<sub>2</sub>Ar), 24.0 (s, CH<sub>2</sub>CH<sub>3</sub>), 23.5 (s, CH<sub>2</sub>CH<sub>3</sub>), 11.0 (s, CH<sub>2</sub>CH<sub>3</sub>), 10.1 (s, CH<sub>2</sub>CH<sub>3</sub>). ESI-MS (CH<sub>3</sub>CN, 180 °C, 3 kV) positive ion: 859.3340 m/z, [M]<sup>+</sup> (calcd 859.3347 m/z). Anal. Calcd For C<sub>80</sub>H<sub>68</sub>AgBF<sub>24</sub>N<sub>4</sub>O<sub>4</sub> (1724.09 g mol<sup>-1</sup>): C, 55.73; H, 3.98; N, 3.25. Found: C, 55.85; H, 4.08; N, 3.33.

### In situ reactions of 4b

A suspension of I<sup>1</sup>Pr<sub>2</sub>Me<sub>2</sub> (9.9 mg, 0.0549 mmol), Ag[OTf] (7.2 mg, 0.0277 mmol) and Na[BAR<sup>F</sup><sub>4</sub>] (24.0 mg, 0.0271 mmol) in difluorobenzene (0.5 mL) was agitated for several minutes. Analysis *in situ* by NMR spectroscopy indicated quantitative formation of 4b (data below). Solutions of 4b, prepared in this way, were then filtered onto either [Rh(COD)Cl]<sub>2</sub> (13.6 mg, 0.0276 mmol) or [Rh(CO)<sub>2</sub>Cl]<sub>2</sub> (10.8 mg, 0.0278 mmol), resulting in the formation of 5b : 7 (2 : 1) and 6b/8 (5 : 2).

<sup>1</sup>H NMR (1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub>, 500 MHz): δ 8.11–8.13 (m, 8H, Ar<sup>F</sup>), 7.49 (br, 4H, Ar<sup>F</sup>), 4.20 (sept, <sup>3</sup>J<sub>HH</sub> = 6.8, 4H, NCH), 1.87 (s, 12H, CCH<sub>3</sub>), 1.31 (d, <sup>3</sup>J<sub>HH</sub> = 6.8, 24H, CHCH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub>, 126 MHz): δ 162.5 (q, <sup>1</sup>J<sub>BC</sub> = 50, Ar<sup>F</sup>), 135.1 (s, Ar<sup>F</sup>), 129.7 (qq, <sup>2</sup>J<sub>FC</sub> = 32, <sup>3</sup>J<sub>BC</sub> = 3, Ar<sup>F</sup>), 124.9 (q, <sup>1</sup>J<sub>FC</sub> = 272, Ar<sup>F</sup>), 124 (obscured, CCH<sub>3</sub>), 117.6 (sept, <sup>3</sup>J<sub>FC</sub> = 4, Ar<sup>F</sup>), 50.1 (s, NCH), 23.3 (s, CHCH<sub>3</sub>), 8.1 (s, CCH<sub>3</sub>). The carbene resonance was not located. <sup>19</sup>F{<sup>1</sup>H} NMR (1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub>, 282 MHz): δ -62.25 (Ar<sup>F</sup>). No signal for [OTf]<sup>-</sup> detected. ESI-MS (CH<sub>3</sub>CN, 180 °C, 3 kV) positive ion: 467.2297 m/z, [M]<sup>+</sup> (calcd 467.2298 m/z).

### Preparation of 5a

A solution of 4a (29.9 mg, 0.0173 mmol) and [Rh(COD)Cl]<sub>2</sub> (9.4 mg, 0.0191 mmol) in 1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub> (0.5 mL) was stirred for 1 hour with the exclusion of light. The solvent was removed *in vacuo* and the resulting crude material washed with pentane and dried *in vacuo*. Yield = 22.3 mg (63%, yellow powder). The product was characterised *in situ*, although has limited stability in solution.

<sup>1</sup>H NMR (1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub>/C<sub>6</sub>D<sub>6</sub>, 500 MHz): δ 8.09–8.15 (m, 8H, Ar<sup>F</sup>), 7.49 (br, 4H, Ar<sup>F</sup>) 5.44 (br, 2H, COD{CH}), 5.38 (br, 2H, COD{CH}), 4.58 (d, <sup>2</sup>J<sub>HH</sub> = 13.6, 2H, ArCH<sub>2</sub>Ar), 4.49 (d, <sup>2</sup>J<sub>HH</sub> = 13.6, 2H, ArCH<sub>2</sub>Ar), 4.20 (s, 6H, NCH<sub>3</sub>), 3.96–4.24 (m), 3.67–3.76 (m), 3.55–3.63 (m), 3.49–3.55 (m), 3.46 (d, <sup>2</sup>J<sub>HH</sub> = 13.6, 2H, ArCH<sub>2</sub>Ar), 3.23–3.33 (m), 3.09 (d, <sup>2</sup>J<sub>HH</sub> = 13.6, 2H,





ArCH<sub>2</sub>Ar), 1.35–2.50 (m, CH<sub>2</sub>), 1.03 (t, <sup>3</sup>J<sub>HH</sub> = 6.9, 6H, CH<sub>2</sub>CH<sub>3</sub>), 0.85 (t, <sup>3</sup>J<sub>HH</sub> = 6.9, 6H, CH<sub>2</sub>CH<sub>3</sub>), 0.7–1.1 (m, COD{CH<sub>2</sub>}). Not all signals unambiguously assigned and some signals obscured by solvent peak. <sup>13</sup>C{<sup>1</sup>H} NMR (1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub>/C<sub>6</sub>D<sub>6</sub>, 126 MHz, selected signals only): δ 176.9 (d, <sup>1</sup>J<sub>RhC</sub> = 50, NCN), 100.3 (br, COD{CH}), 96.4 (br, COD{CH}), 78.5 (d, <sup>1</sup>J<sub>RhC</sub> = 14, COD{CH}), 71.8 (d, <sup>1</sup>J<sub>RhC</sub> = 13, COD{CH}), 97.7 (d, <sup>1</sup>J<sub>RhC</sub> = 7, COD{CH}), 70.2 (d, <sup>1</sup>J<sub>RhC</sub> = 16, COD{CH}), 37.8 (s, NCH<sub>3</sub>). **ESI-MS** (CH<sub>3</sub>CN, 180 °C, 3 kV): positive ion: 1209.3986 *m/z*, [M]<sup>+</sup> (calcd 1209.3973 *m/z*).

### Preparation of 5b

A solution of [Rh(<sup>1</sup>Pr<sub>2</sub>Me<sub>2</sub>)(COD)Cl] (23.6 mg, 0.0553 mmol) and Na[BAR<sup>F</sup><sub>4</sub>] (24.5 mg, 0.0275 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was stirred for 1 hour. The solution was then filtered and layered with pentane to afford the product on diffusion. Yield = 32.0 mg (69%, yellow crystals).

<sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 500 MHz): δ 7.70–7.74 (m, 8H, Ar<sup>F</sup>), 7.56 (br, 4H, Ar<sup>F</sup>), 5.91 (sept, <sup>3</sup>J<sub>HH</sub> = 7.1, 4H, NCH), 4.75 (s, 4H, COD{CH}), 3.51 (s, 4H, COD{CH}), 2.22–2.36 (m, 8H, COD{CH<sub>2</sub>}), 2.11 (s, 12H, CCH<sub>3</sub>), 1.81–1.93 (m, 8H, COD{CH<sub>2</sub>}), 1.57 (d, <sup>3</sup>J<sub>HH</sub> = 7.0, 12H, CHCH<sub>3</sub>), 1.36 (d, <sup>3</sup>J<sub>HH</sub> = 7.0, 12H, CHCH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>, 126 MHz): δ 175.6 (d, <sup>1</sup>J<sub>RhC</sub> = 50, NCN), 162.3 (q, <sup>1</sup>J<sub>BC</sub> = 51, Ar<sup>F</sup>), 135.4 (s, Ar<sup>F</sup>), 129.4 (qq, <sup>2</sup>J<sub>FC</sub> = 31, <sup>3</sup>J<sub>BC</sub> = 3, Ar<sup>F</sup>), 126.3 (s, CCH<sub>3</sub>), 125.2 (q, <sup>1</sup>J<sub>FC</sub> = 272, Ar<sup>F</sup>), 118.0 (sept, <sup>3</sup>J<sub>FC</sub> = 4, Ar<sup>F</sup>), 97.7 (d, <sup>1</sup>J<sub>RhC</sub> = 7, COD{CH}), 70.2 (d, <sup>1</sup>J<sub>RhC</sub> = 16, COD{CH}), 54.3 (s, NCH), 33.1 (s, COD{CH<sub>2</sub>}), 29.1 (s, COD{CH<sub>2</sub>}), 22.5 (s, CHCH<sub>3</sub>), 22.2 (s, CHCH<sub>3</sub>), 10.5 (s, CCH<sub>3</sub>). **ESI-MS** (CH<sub>3</sub>CN, 180 °C, 3 kV) positive ion: 817.2872 *m/z*, [M]<sup>+</sup> (calcd 817.2924 *m/z*). **Anal.** Calcd For C<sub>70</sub>H<sub>76</sub>BF<sub>24</sub>N<sub>4</sub>Rh<sub>2</sub>Cl (1434.39 g mol<sup>-1</sup>): C, 49.97; H, 4.56; N, 3.33. Found: C, 50.18; H, 4.52; N, 3.23.

### Preparation of 6a

A solution of **4a** (32.0 mg, 0.0186 mmol) and [Rh(CO)<sub>2</sub>Cl]<sub>2</sub> (7.8 mg, 0.0201 mmol) in 1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub> (10 mL) was stirred for one hour with the exclusion of light. The cloudy yellow solution was filtered, reduced to dryness and the resulting residue washed with pentane. Yield = 21.4 mg (31%, yellow powder). The product was characterised *in situ*, although has limited stability in solution.

<sup>1</sup>H NMR (1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub>/C<sub>6</sub>D<sub>6</sub>, 500 MHz): δ 8.11–8.15 (m, 8H, Ar<sup>F</sup>), 7.49 (br, 4H, Ar<sup>F</sup>), 4.52 (d, <sup>2</sup>J<sub>HH</sub> = 12.6, 2H, ArCH<sub>2</sub>Ar), 4.51 (d, <sup>2</sup>J<sub>HH</sub> = 12.6, 2H, ArCH<sub>2</sub>Ar), 4.05–4.19 (m, 2H, OCH<sub>2</sub>), 3.88–3.99 (m, 2H, OCH<sub>2</sub>), 3.84 (s, 6H, NCH<sub>3</sub>), 3.51–3.65 (m, 4H, OCH<sub>2</sub>), 3.18 (d, <sup>2</sup>J<sub>HH</sub> = 12.6, 2H, ArCH<sub>2</sub>Ar), 3.15 (d, <sup>2</sup>J<sub>HH</sub> = 12.6, 2H, ArCH<sub>2</sub>Ar), 2.11–2.23 (m, 4H, CH<sub>2</sub>CH<sub>3</sub>), 1.79–1.92 (m, 4H, CH<sub>2</sub>CH<sub>3</sub>), 0.94 (t, <sup>3</sup>J<sub>HH</sub> = 7.5, 6H, CH<sub>2</sub>CH<sub>3</sub>), 0.93 (t, <sup>3</sup>J<sub>HH</sub> = 7.5, 6H, CH<sub>2</sub>CH<sub>3</sub>). Some signals obscured by solvent peak. <sup>13</sup>C{<sup>1</sup>H} NMR (1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub>/C<sub>6</sub>D<sub>6</sub>, 126 MHz, selected signals only): δ 182.7 (d, <sup>1</sup>J<sub>RhC</sub> = 53, CO), 181.0 (d, <sup>1</sup>J<sub>RhC</sub> = 80, CO), 168.1 (d, <sup>1</sup>J<sub>RhC</sub> = 43, NCN), 36.3 (s, NCH<sub>3</sub>). **ESI-MS** (CH<sub>3</sub>CN, 180 °C, 3 kV) positive ion: 1105.1680 *m/z*, [M]<sup>+</sup> (calcd 1105.1891 *m/z*). **IR** (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>): ν(CO) 2083, 2016.

### Preparation of 6b

A solution of [Rh(<sup>1</sup>Pr<sub>2</sub>Me<sub>2</sub>)(CO)<sub>2</sub>Cl] (26.5 mg, 0.709 mmol) and Na[BAR<sup>F</sup><sub>4</sub>] (32.6 mg, 0.368 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was stirred for one hour. The solution was then filtered and layered with pentane to afford the product on diffusion. Yield = 37.1 mg (66%, yellow crystals).

<sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz): δ 7.67–7.77 (m, 8H, Ar<sup>F</sup>), 7.56 (br, 4H, Ar<sup>F</sup>), 5.20 (sept, <sup>3</sup>J<sub>HH</sub> = 7.1, 4H, NCH), 2.18 (s, 12H, CCH<sub>3</sub>), 1.55 (d, <sup>3</sup>J<sub>HH</sub> = 7.1, 12H, CHCH<sub>3</sub>), 1.50 (d, <sup>3</sup>J<sub>HH</sub> = 7.0, 12H, CHCH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>, 101 MHz): δ 185.4 (d, <sup>1</sup>J<sub>RhC</sub> = 53, CO), 181.0 (d, <sup>1</sup>J<sub>RhC</sub> = 84, CO), 162.3 (q, <sup>1</sup>J<sub>BC</sub> = 50, Ar<sup>F</sup>), 135.4 (s, Ar<sup>F</sup>), 129.4 (qq, <sup>2</sup>J<sub>FC</sub> = 32, <sup>3</sup>J<sub>BC</sub> = 3, Ar<sup>F</sup>), 128.0 (s, CCH<sub>3</sub>), 125.2 (q, <sup>1</sup>J<sub>FC</sub> = 272, Ar<sup>F</sup>), 54.8 (s, NCH), 22.8 (s, CHCH<sub>3</sub>)<sub>2</sub>, 22.4 (s, CHCH<sub>3</sub>)<sub>2</sub>, (s, 10.6 CCH<sub>3</sub>). The carbene resonance was not located. **ESI-MS** (CH<sub>3</sub>CN, 180 °C, 3 kV) positive ion: 713.0829 *m/z*, [M]<sup>+</sup> (calcd 713.0843 *m/z*). **IR** (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>): ν(CO) 2090, 2019. **Anal.** Calcd For C<sub>58</sub>H<sub>52</sub>BClF<sub>24</sub>N<sub>4</sub>O<sub>4</sub>Rh<sub>2</sub>Cl (1577.11 g mol<sup>-1</sup>): C, 44.17; H, 3.32; N, 3.55. Found: C, 44.51; H, 3.57; N, 3.49.

### Preparation of 7

A solution of <sup>1</sup>Pr<sub>2</sub>Me<sub>2</sub> (50.8 mg, 0.282 mmol), [Rh(COD)Cl]<sub>2</sub> (34.3 mg, 0.0696 mmol) and Na[BAR<sup>F</sup><sub>4</sub>] (123.4 mg, 0.139 mmol) was stirred in 1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub> (5 mL) for 2.5 h. The solution was then filtered and layered with pentane to afford the product on diffusion. Yield = 114.0 mg (56%, yellow crystals).

<sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 500 MHz): δ 7.71–7.75 (m, 8H, Ar<sup>F</sup>), 7.56 (br, 4H, Ar<sup>F</sup>), 5.56 (sept, <sup>3</sup>J<sub>HH</sub> = 7.1, 4H, NCH), 4.27 (s, 4H, COD{CH}), 2.31–2.40 (m, 4H, COD{CH<sub>2</sub>}), 2.16 (s, 12H, CCH<sub>3</sub>), 2.01–2.11 (m, 4H, COD{CH<sub>2</sub>}), 1.55 (d, <sup>3</sup>J<sub>HH</sub> = 7.1, 12H, CHCH<sub>3</sub>), 1.22 (d, <sup>3</sup>J<sub>HH</sub> = 7.1, 12H, CHCH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>, 126 MHz): δ 178.1 (d, <sup>1</sup>J<sub>RhC</sub> = 55.8, NCN), 162.3 (q, <sup>1</sup>J<sub>BC</sub> = 50, Ar<sup>F</sup>), 135.4 (s, Ar<sup>F</sup>), 129.4 (qq, <sup>2</sup>J<sub>FC</sub> = 32, <sup>3</sup>J<sub>BC</sub> = 3, Ar<sup>F</sup>), 127.1 (s, CCH<sub>3</sub>), 125.2 (q, <sup>1</sup>J<sub>FC</sub> = 272, Ar<sup>F</sup>), 118.0 (sept, <sup>3</sup>J<sub>FC</sub> = 4, Ar<sup>F</sup>), 87.2 (d, <sup>1</sup>J<sub>RhC</sub> = 8, COD{CH}), 54.5 (s, NCH), 31.8 (s, COD{CH}), 22.9 (s, CHCH<sub>3</sub>), 21.6 (s, CHCH<sub>3</sub>), 10.9 (s, CCH<sub>3</sub>). **ESI-MS** (CH<sub>3</sub>CN, 180 °C, 3 kV) positive ion: 571.3215 *m/z*, [M]<sup>+</sup> (calcd 571.3242 *m/z*). **Anal.** Calcd For C<sub>62</sub>H<sub>64</sub>BF<sub>24</sub>N<sub>4</sub>Rh (1434.39 g mol<sup>-1</sup>): C, 51.96; H, 4.49; N, 3.90. Found: C, 52.05; H, 4.59; N, 3.93.

### Preparation of 8

A solution of **7** (113.9 mg, 0.0794 mmol) in 1,2-C<sub>6</sub>H<sub>4</sub>F<sub>2</sub> (5 mL) was stirred under an atmosphere of CO (1 atm) for 24 hours. The solvent was removed *in vacuo* and the resulting crude material washed with pentane and recrystallised from CH<sub>2</sub>Cl<sub>2</sub>/pentane. Yield = 72.4 mg (66%, orange powder).

<sup>1</sup>H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 500 MHz): δ 7.71–7.75 (m, 8H, Ar<sup>F</sup>), 7.56 (br, 4H, Ar<sup>F</sup>), 5.05 (sept, <sup>3</sup>J<sub>HH</sub> = 7.1, 4H, NCH), 2.20 (s, 12H, CCH<sub>3</sub>), 1.46 (d, <sup>3</sup>J<sub>HH</sub> = 7.1, 12H, CHCH<sub>3</sub>), 1.19 (d, <sup>3</sup>J<sub>HH</sub> = 7.1, 12H, CHCH<sub>3</sub>). <sup>13</sup>C{<sup>1</sup>H} NMR (CD<sub>2</sub>Cl<sub>2</sub>, 126 MHz): δ 186.9 (d, <sup>1</sup>J<sub>RhC</sub> = 57, CO), 168.2 (d, <sup>1</sup>J<sub>RhC</sub> = 47, NCN), 162.3 (q, <sup>1</sup>J<sub>BC</sub> = 50, Ar<sup>F</sup>), 135.3 (s, Ar<sup>F</sup>), 129.4 (qq, <sup>2</sup>J<sub>FC</sub> = 32, <sup>3</sup>J<sub>BC</sub> = 3, Ar<sup>F</sup>), 128.2 (s, CCH<sub>3</sub>), 125.2 (q, <sup>1</sup>J<sub>FC</sub> = 272, Ar<sup>F</sup>), 118.0 (sept, <sup>3</sup>J<sub>FC</sub> = 4, Ar<sup>F</sup>), 55.3 (s, NCH), 22.0 (s, CHCH<sub>3</sub>), 21.1 (s, CHCH<sub>3</sub>), 10.9 (s, CCH<sub>3</sub>).



**ESI-MS** ( $\text{CH}_3\text{CN}$ , 180 °C, 3 kV) positive ion: 519.2249  $m/z$  [ $\text{M}$ ]<sup>+</sup> (calcd 520.2201  $m/z$ ). **IR** ( $\text{CH}_2\text{Cl}_2$ ,  $\text{cm}^{-1}$ ):  $\nu(\text{CO})$  2077, 2018. **Anal.** Calcd For  $\text{C}_{56}\text{H}_{52}\text{BF}_{24}\text{N}_4\text{Rh}$  (1382.29  $\text{g mol}^{-1}$ ): C, 48.64; H, 3.79; N, 4.05. Measured: C, 48.51; H, 3.63; N, 4.15.

### Crystallography

Full details about the collection, solution and refinement are documented in the CIF, which have been deposited with the Cambridge Crystallographic Data Centre under CCDC 1448987–1448996.

## Acknowledgements

We thank the Royal Society (A. B. C.), EPSRC (R. P.) and University of Warwick for financial support. Crystallographic and high-resolution mass-spectrometry data were collected using instruments purchased through support from Advantage West Midlands and the European Regional Development Fund.

## References

- (a) S. Díez-González, N. Marion and S. P. Nolan, *Chem. Rev.*, 2009, **109**, 3612–3676; (b) C. Samojłowicz, M. Bieniek and K. Grela, *Chem. Rev.*, 2009, **109**, 3708–3742; (c) F. E. Hahn and M. C. Jahnke, *Angew. Chem., Int. Ed.*, 2008, **47**, 3122–3172; (d) M. N. Hopkinson, C. Richter, M. Schedler and F. Glorius, *Nature*, 2014, **510**, 485–496.
- L. Benhamou, E. Chardon, G. Lavigne, S. Bellemin-Laponnaz and V. Cesar, *Chem. Rev.*, 2011, **111**, 2705–2733.
- (a) R. E. Andrew, L. González-Sebastián and A. B. Chaplin, *Dalton Trans.*, 2016, **45**, 1299–1305; (b) X. Hu, I. Castro-Rodríguez and K. Meyer, *J. Am. Chem. Soc.*, 2003, **125**, 12237–12245; (c) E. Peris and R. H. Crabtree, *Coord. Chem. Rev.*, 2004, **248**, 2239–2246; (d) J. A. Mata, M. Poyatos and E. Peris, *Coord. Chem. Rev.*, 2007, **251**, 841–859; (e) D. Pugh and A. A. Danopoulos, *Coord. Chem. Rev.*, 2007, **251**, 610–641; (f) M. Poyatos, J. A. Mata and E. Peris, *Chem. Rev.*, 2009, **109**, 3677–3707; (g) C. Radloff, H.-Y. Gong, C. Schulte to Brinke, T. Pape, V. M. Lynch, J. L. Sessler and F. E. Hahn, *Chem. – Eur. J.*, 2010, **16**, 13077–13081; (h) R. E. Andrew and A. B. Chaplin, *Dalton Trans.*, 2014, **43**, 1413–1423.
- (a) V. Böhmer, *Angew. Chem., Int. Ed. Engl.*, 1995, **34**, 713–745; (b) B. R. Cameron, S. J. Loeb and G. P. A. Yap, *Inorg. Chem.*, 1997, **36**, 5498–5504; (c) C. Wieser, C. Dieleman and D. Matt, *Coord. Chem. Rev.*, 1997, **165**, 93–161; (d) P. Molenveld, J. Engbersen and D. Reinhoudt, *Chem. Soc. Rev.*, 2000, **29**, 75–86; (e) P. D. Harvey, *Coord. Chem. Rev.*, 2002, **233–234**, 289–309; (f) C. Jeunesse, D. Armspach and D. Matt, *Chem. Commun.*, 2005, **2005**, 5603–5614; (g) D. M. Homden and C. Redshaw, *Chem. Rev.*, 2008, **108**, 5086–5130; (h) B. S. Creaven, D. F. Donlon and J. McGinley, *Coord. Chem. Rev.*, 2009, **253**, 893–962.
- Selected examples relevant to this work. (a) T. Brendgen, M. Frank and J. Schatz, *Eur. J. Org. Chem.*, 2006, 2378–2383; (b) E. Brenner, D. Matt, M. Henrion, M. Teci and L. Toupet, *Dalton Trans.*, 2011, **40**, 9889–9898; (c) H. Ren, Y. Xu, E. Jeanneau, I. Bonnamour, T. Tu and U. Darbost, *Tetrahedron*, 2014, **70**, 2829–2837.
- I. Dinarès, C. Garcia de Miguel, M. Font-Bardia, X. Solans and E. Alcalde, *Organometallics*, 2007, **26**, 5125–5128.
- (a) M. Frank, G. Maas and J. Schatz, *Eur. J. Org. Chem.*, 2004, 607–613; (b) T. Fahlbusch, M. Frank, G. Maas and J. Schatz, *Organometallics*, 2009, **28**, 6183–6193.
- (a) C. Wieser-Jeunesse, D. Matt and A. De Cian, *Angew. Chem., Int. Ed.*, 1998, **37**, 2861–2864; (b) M. Lejeune, C. Jeunesse, D. Matt, N. Kyritsakas, R. Welter and J.-P. Kintzinger, *J. Chem. Soc., Dalton Trans.*, 2002, 1642–1650.
- Dinuclear complexes, polymeric complexes, and mono-nuclear complexes with *cis*-coordination geometries can also be obtained using this and related diphosphine ligands: (a) I. A. Bagatin, D. Matt, H. Thönnessen and P. G. Jones, *Inorg. Chem.*, 1999, **38**, 1585–1591; (b) X. Fang, B. L. Scott, J. G. Watkin, C. A. G. Carter and G. J. Kubas, *Inorg. Chim. Acta*, 2001, **317**, 276–281; (c) K. Takenaka, Y. Obora, L. H. Jiang and Y. Tsuji, *Organometallics*, 2002, **21**, 1158–1166; ref. 8b; (d) F. Plourde, K. Gilbert, J. Gagnon and P. D. Harvey, *Organometallics*, 2003, **22**, 2862–2875; (e) M. Lejeune, D. Sémeril, C. Jeunesse, D. Matt, F. Peruch, P. J. Lutz and L. Ricard, *Chem. – Eur. J.*, 2004, **10**, 5354–5360; (f) L. Monnereau, D. Sémeril, D. Matt, L. Toupet and A. J. Mota, *Adv. Synth. Catal.*, 2009, **351**, 1383–1389; (g) S. Sameni, C. Jeunesse, M. Awada, D. Matt and R. Welter, *Eur. J. Inorg. Chem.*, 2010, **2010**, 4917–4923; (h) L. Monnereau, D. Sémeril, D. Matt and L. Toupet, *Polyhedron*, 2013, **51**, 70–74.
- N. Kuhn and T. Kratz, *Synthesis*, 1993, 561–562.
- I. Dinarès, C. Garcia de Miguel, N. Mesquida and E. Alcalde, *J. Org. Chem.*, 2009, **74**, 482–485.
- Preparation from 4-*tert*-butylcalix[4]arene: (a) C. D. Gutsche and L.-G. Lin, *Tetrahedron*, 1986, **42**, 1633–1640 (alkyl group transfer; 1 day, 51% yield); (b) A. Dondoni, C. Ghigliione, A. Marra and M. Scoponi, *Macromol. Chem. Phys.*, 1999, **200**, 77–86 (alkylation; overnight reaction, 66% yield); (c) M. Larsen and M. Jørgensen, *J. Org. Chem.*, 1996, **61**, 6651–6655 (bromination; overnight reaction, 80% yield; lithium halogen exchange; 1 day, 49% yield); (d) Ref. 11 (Cu-catalyzed Ullmann reaction; ca. 7 day reaction, 62% yield).
- For two representative examples see: (a) J. Scheerder, R. H. Vreekamp, J. F. J. Engbersen, W. Verboom, J. P. M. van Duynhoven and D. N. Reinhoudt, *J. Org. Chem.*, 1996, **61**, 3476–3481; (b) M. Conner, V. Janout and S. L. Regen, *J. Am. Chem. Soc.*, 1991, **113**, 9670–9671.
- (a) D. Tapu, D. A. Dixon and C. Roe, *Chem. Rev.*, 2009, **109**, 3385–3407; (b) T. Dröge and F. Glorius, *Angew. Chem., Int. Ed.*, 2010, **49**, 6940–6952.
- (a) S.-I. Fuku-en, J. Yamamoto, M. Minoura, S. Kojima and Y. Yamamoto, *Inorg. Chem.*, 2013, **52**, 11700–11702; (b) G. T. S. Andavan, E. B. Bauer, C. S. Letko, T. K. Hollis



- and F. S. Tham, *J. Organomet. Chem.*, 2005, **690**, 5938–5947; (c) M. V. Baker, S. K. Brayshaw, B. W. Skelton and A. H. White, *Inorg. Chim. Acta*, 2004, **357**, 2841–2849; (d) M. Poyatos, M. Sanau and E. Peris, *Inorg. Chem.*, 2003, **42**, 2572–2576.
- 16 (a) I. J. B. Lin and C. S. Vasam, *Coord. Chem. Rev.*, 2007, **251**, 642–670; (b) J. C. Garrison and W. J. Youngs, *Chem. Rev.*, 2005, **105**, 3978–4008.
- 17 E. Oehlke, T. Kückmann and U. Abram, *Z. Anorg. Allg. Chem.*, 2007, **633**, 830–834.
- 18 (a) S. A. Hauser, R. Tonner and A. B. Chaplin, *Organometallics*, 2015, **34**, 4419–4427; (b) L. J. Sewell, M. A. Huertos, M. E. Dickinson, A. S. Weller and G. C. Lloyd-Jones, *Inorg. Chem.*, 2013, **52**, 4509–4516; (c) C. Y. Tang, J. Lednik, D. Vidovic, A. L. Thompson and S. Aldridge, *Chem. Commun.*, 2011, **47**, 2523–2525; (d) F. Ekkehardt Hahn, B. Heidrich, T. Pape, A. Hepp, M. Martín, E. Sola and L. A. Oro, *Inorg. Chim. Acta*, 2006, **359**, 4840–4846.
- 19 G. Giordano, R. H. Crabtree, R. M. Heintz, D. Forster and D. E. Morris, *Inorg. Synth.*, 1990, **28**, 88–90.
- 20 J. A. McCleverty, G. Wilkinson, L. G. Lipson, M. L. Maddox and H. D. Kaesz, *Inorg. Synth.*, 1990, **28**, 84–86.
- 21 W. E. Buschmann, J. S. Miller, K. Bowman-James and C. N. Miller, *Inorg. Synth.*, 2002, **33**, 83–91.
- 22 A. Neveling, G. R. Julius, S. Cronje, C. Esterhuysen and H. G. Raubenheimer, *Dalton Trans.*, 2005, 181–192.

